Navigation Links
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Date:10/27/2011

onded primarily to increases in (1) professional fees in connection with various completed and prospective transactions; (2) salaries and business development-related expenses resulting from our growth; and (3) grants to unaffiliated not-for-profit organizations.

Sales and marketing. The increase in sales and marketing expenses for the quarter ended September 30, 2011, compared to the quarter ended September 30, 2010, was attributable to an increase in salaries resulting principally from the expansion of our sales force and an increase in professional fees in connection with our marketing and advertising initiatives.

Share-based compensation. The decrease in share-based compensation for the quarter ended September 30, 2011, compared to the same quarter in 2010, reflects a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decline in our stock price.

Income Taxes

The provision for income taxes was $17.6 million for the quarter ended September 30, 2011, compared to $18.2 million for the same quarter in 2010. The estimated annual effective tax rates were approximately 28 percent and 36 percent as of September 30, 2011 and 2010, respectively. The decrease in the annual effective tax rate as of September 30, 2011 largely reflects reductions in annual estimates of non-deductible compensation and an increase in tax credits expected to be generated.

2011 Revenue GuidanceWe reaffirm our 2011 full-year revenue guidance for our three commercial products (Remodulin, Tyvaso and Adcirca), as we continue to expect related revenues to fall within a range of 5% above or below $750 million for 2011.

Note Regarding Discontinued OperationsResults for the three- and nine-month periods ended September 30, 2011 and September 30, 2010 do not include the results of Medicomp, Inc. (Medicomp), our former telemedicine subsidiary, which we sold during the fir
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
2. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
3. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
4. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
5. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
6. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
7. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
8. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
9. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
10. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
11. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... MA (PRWEB) October 25, 2014 ... products, is pleased to announce the release of ... the highest level of contamination containment in critical ... Class 3 and higher cleanroom environments, ValuSeal® IonX™ ... polyester knit laundered wiper that continues Berkshire’s innovative ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... Oct. 22, 2014 Research and ... "Global DNA Diagnostics Market (Product types, Application, ... Global Trends, Company Profiles, Demand, Insights, Analysis, Research, ... report to their offering. ... applications, techniques, end users and Geography) Global Size, ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... SHANGHAI, June 16 /PRNewswire-Asia/ -- ... announced,today that its animal facility in Shanghai has passed ... Sundia management and staff are praised,for providing good facilities ... , The inspection and audit ...
... June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: ... of its,recently completed international Phase III trial of Bronchitol in ... Cystic Fibrosis,Conference in Brest, France. , ... June by Dr Diana,Bilton of the Royal Brompton Hospital, London. ...
... , DETROIT, June 15 Business, nonprofit and ... the manufacturing sector that includes enacting pro-industry policies and ... investment, and creating new demand through innovation and globalization. ... at The National Summit in Detroit agreed that economic ...
Cached Biology Technology:Sundia's Animal Facility Passed Client and Government Inspection 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 2Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 3
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... One in eight women in the United States will receive ... is the second leading cause of cancer-related death in women. ... possible treatment for each patient. "Our research shows that ... without getting any treatment at all, other than a lumpectomy," ...
... mobile phone charger at home when you go for ... norm one day as scientists from Nanyang Technological University ... a microchip that uses 30 times less electricity while ... The technology, dubbed PCMOS (probabilistic complementary metal-oxide semiconductor) was ...
... of genetic factors associated with heart attacks has identified ... that appear to increase the risk for early-onset myocardial ... Consortium, based on information from a total of 26,000 ... Genetics and is receiving early online release. ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 3International study identifies gene variants associated with early heart attack 2International study identifies gene variants associated with early heart attack 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... the Beacon 2000 instrument can be used ... Beacon 2000 Data Manager Software provides the ... directly from the instrument. These data can ... available spreadsheets, such as Microsoft Excel or ...
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... self locking design in ice/water bath ... product number, created to easily match ... availability yet, please order under the ... customer service for assistance. ID clarifier: ...
Biology Products: